Table 3. Multiplicative Interaction Results, Combined sCD14 and sCD23 Levels (Dichotomous Groupings), Stratified by Histologic Type and Dexamethasone Use, San Francisco Bay Area Adult Glioma Study Participants (1997-2006).

		Number
Case Grouping	Dichotomous Grouping**	Cases	Controls	OR* (95% CI)	Multiplicative p values
All Cases	Low sCD14 / High sCD23	276	416	1.00
	Low sCD14 / Low sCD23	221	133	2.6 (2.0-3.4)
	High sCD14 / High sCD23	344	126	4.7 (3.6-6.2)
	High sCD14 / Low sCD23	222	51	7.2 (5.1-10.3)	0.03
Cases Taking Dexamethasone	Low sCD14 / High sCD23	87	416	1.00
	Low sCD14 / Low sCD23	113	133	4.1 (2.9-5.8)
	High sCD14 / High sCD23	136	126	5.8 (4.1-8.1)
	High sCD14 / Low sCD23	115	51	11.8 (7.8-17.8)	0.01
Cases Not Taking Dexamethasone	Low sCD14 / High sCD23	189	416	1.00
	Low sCD14 / Low sCD23	108	133	1.8 (1.3-2.5)
	High sCD14 / High sCD23	208	126	4.3 (3.2-5.7)
	High sCD14 / Low sCD23	107	51	5.0 (3.4-7.4)	0.10
Glioblastoma Cases	Low sCD14 / High sCD23	134	416	1.00
	Low sCD14 / Low sCD23	134	133	3.2 (2.3-4.3)
	High sCD14 / High sCD23	189	126	5.1 (3.7-6.9)
	High sCD14 / Low sCD23	151	51	9.8 (6.7-14.3)	0.05
Non-Glioblastoma Cases	Low sCD14 / High sCD23	142	416	1.00
	Low sCD14 / Low sCD23	86	133	1.9 (1.4-2.8)
	High sCD14 / High sCD23	155	126	4.5 (3.3-6.3)
	High sCD14 / Low sCD23	71	51	4.7 (3.1-7.3)	0.04

^*Odds ratios were estimated in logistsic regression models adjusted for age (continuous), gender, race (white/non-white), education (college vs no college), and smoking (ever vs never).

The stratified results were estimated using polytomous regression models.

^**Cutoff points for dichotomizing the concentration of sCD14 was 9.30 ug/mL and for sCD23 was 1.59 ng/mL.